Trial Profile
A Phase I/II, Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Endometrial Cancer or Squamous NSCLC
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jul 2023
Price :
$35
*
At a glance
- Drugs ABTL 0812 (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Endometrial cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Endolung
- Sponsors Ability Pharmaceuticals
- 06 Jun 2023 Results(n=40) assessing the safety of ABTL0812 in combination with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 01 Jun 2023 Results presented in the Ability Pharmaceuticals Media Release.
- 01 Jun 2023 According to an Ability Pharmaceuticals media release, final results of the phase 2a will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.